Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and
neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting …

This article presents an overview of imaging agents for PET that have been applied for
research and diagnostic purposes in patients affected by dementia. Classified by the target …

Background Targeted delivery of nerve growth factor (NGF) has emerged as a potential
therapy for Alzheimer's disease (AD) due to its regenerative effects on basal forebrain …

OBJECTIVES: To evaluate the effect of cholinesterase inhibitors (ChEIs) and memantine on
the risk of falls, syncope, and related events, defined as fracture and accidental injury …

Purpose: Nasal galantamine hydrobromide (GH)/chitosan complex nanoparticles (CX-NP2)
could have an improved therapeutic potential for managing Alzheimer's disease (AD). The …

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by
cognitive decline associated with a deficit in cholinergic function. Inhibitors of …

Dimethyl sulfoxide (DMSO) is the most common organic solvent used in biochemical and
cellular assays during drug discovery programs. Despite its wide use, the effect of DMSO on …

NEUROTRANSMITTER MEASURES IN THE CEREBROSPINAL FLUID OF PATIENTS WITH
ALZHEIMER'S DISEASE: A REVIEW Page 1 14 Psychiatria Danubina, 2015; Vol. 27, No. 1, pp …

Introduction Alzheimer's disease (AD) is the most prevalent form of dementia with symptoms
of deteriorating cognitive functions and memory loss, partially as a result of a decrease in …

Introduction The extensive loss of central cholinergic functions in Alzheimer's disease (AD)
brain is linked to impaired nerve growth factor (NGF) signaling. The cardinal cholinergic …